OBJECTIVE: To study the effects of oxidative stress on prostate cancer development as the exact biological mechanisms behind the relationship remain uncertain. We previously reported a statistically significant interaction between circulating selenium levels, variants in the superoxide dismutase 2 gene (SOD2; rs4880), and risk of developing prostate cancer and presenting with aggressive prostate cancer. PATIENTS AND METHODS: We genotyped men with localized/regional prostate cancer for 26 loci across eight genes that are central to cellular antioxidant defence: glutathione peroxidase (GPX1, GPX4), peroxisome proliferator-activated receptor γ coactivator (PPARGC1A, PPARGC1B), SOD1, SOD2, and SOD3, and 'X-ray repair complementing defective repair in Chinese hamster cell 1' (XRCC1). Among 489 men, we examined the relationships between genotypes, circulating selenium levels, and risk of presenting with aggressive prostate cancer at diagnosis, as defined by stage, grade and prostate-specific antigen (PSA) level (213 aggressive cases). RESULTS: Two variants in SOD2 were significantly associated with the risk of aggressive prostate cancer (rs17884057, odds ratio 0.83, 95% confidence interval 0.70-0.99; and rs4816407, 1.27, 1.02-1.57); men with A alleles at rs2842958 in SOD2 had lower plasma selenium levels (median 116 vs 121.8 µg/L, P= 0.03); and the association between plasma selenium levels and risk of aggressive prostate cancer was modified by SOD1 (rs10432782) and SOD2 (rs2758330). CONCLUSION: While this study was cross-sectional and these associations might be due to chance, further research is warranted on the potential important role of antioxidant defence in prostate cancer.
OBJECTIVE: To study the effects of oxidative stress on prostate cancer development as the exact biological mechanisms behind the relationship remain uncertain. We previously reported a statistically significant interaction between circulating selenium levels, variants in the superoxide dismutase 2 gene (SOD2; rs4880), and risk of developing prostate cancer and presenting with aggressive prostate cancer. PATIENTS AND METHODS: We genotyped men with localized/regional prostate cancer for 26 loci across eight genes that are central to cellular antioxidant defence: glutathione peroxidase (GPX1, GPX4), peroxisome proliferator-activated receptor γ coactivator (PPARGC1A, PPARGC1B), SOD1, SOD2, and SOD3, and 'X-ray repair complementing defective repair in Chinese hamster cell 1' (XRCC1). Among 489 men, we examined the relationships between genotypes, circulating selenium levels, and risk of presenting with aggressive prostate cancer at diagnosis, as defined by stage, grade and prostate-specific antigen (PSA) level (213 aggressive cases). RESULTS: Two variants in SOD2 were significantly associated with the risk of aggressive prostate cancer (rs17884057, odds ratio 0.83, 95% confidence interval 0.70-0.99; and rs4816407, 1.27, 1.02-1.57); men with A alleles at rs2842958 in SOD2 had lower plasma selenium levels (median 116 vs 121.8 µg/L, P= 0.03); and the association between plasma selenium levels and risk of aggressive prostate cancer was modified by SOD1 (rs10432782) and SOD2 (rs2758330). CONCLUSION: While this study was cross-sectional and these associations might be due to chance, further research is warranted on the potential important role of antioxidant defence in prostate cancer.
Authors: Piet A van den Brandt; Maurice P A Zeegers; Peter Bode; R Alexandra Goldbohm Journal: Cancer Epidemiol Biomarkers Prev Date: 2003-09 Impact factor: 4.254
Authors: Nishi Karunasinghe; Jacqueline Ryan; John Tuckey; Jonathan Masters; Michael Jamieson; Larry C Clarke; James R Marshall; Lynnette R Ferguson Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-03 Impact factor: 4.254
Authors: Karen Woodson; Joseph A Tangrea; Teresa A Lehman; Ramakrishna Modali; Kristin M Taylor; Kirk Snyder; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes Journal: Cancer Causes Control Date: 2003-08 Impact factor: 2.506
Authors: Z Kote-Jarai; F Durocher; S M Edwards; R Hamoudi; R A Jackson; A Ardern-Jones; A Murkin; D P Dearnaley; R Kirby; R Houlston; D F Easton; R Eeles Journal: Prostate Cancer Prostatic Dis Date: 2002 Impact factor: 5.554
Authors: Tara M Vogt; Regina G Ziegler; Barry I Graubard; Christine A Swanson; Raymond S Greenberg; Janet B Schoenberg; G Marie Swanson; Richard B Hayes; Susan T Mayne Journal: Int J Cancer Date: 2003-02-20 Impact factor: 7.396
Authors: A J Duffield-Lillico; B L Dalkin; M E Reid; B W Turnbull; E H Slate; E T Jacobs; J R Marshall; L C Clark Journal: BJU Int Date: 2003-05 Impact factor: 5.588
Authors: David J Waters; Shuren Shen; Dawn M Cooley; David G Bostwick; Junqi Qian; Gerald F Combs; Lawrence T Glickman; Carol Oteham; Deborah Schlittler; J Steven Morris Journal: J Natl Cancer Inst Date: 2003-02-05 Impact factor: 13.506
Authors: Erin L Van Blarigan; Jing Ma; Stacey A Kenfield; Meir J Stampfer; Howard D Sesso; Edward L Giovannucci; John S Witte; John W Erdman; June M Chan; Kathryn L Penney Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-04-07 Impact factor: 4.254
Authors: Philip W Kantoff; Lorelei A Mucci; June M Chan; Amy K Darke; Kathryn L Penney; Catherine M Tangen; Phyllis J Goodman; Gwo-Shu Mary Lee; Tong Sun; Sam Peisch; Alex M Tinianow; James M Rae; Eric A Klein; Ian M Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-06 Impact factor: 4.254
Authors: Erin E Martinez; Amy K Darke; Catherine M Tangen; Phyllis J Goodman; Jay H Fowke; Eric A Klein; Sarki A Abdulkadir Journal: Cancer Prev Res (Phila) Date: 2014-06-03
Authors: John P Gerstenberger; Scott R Bauer; Erin L Van Blarigan; Eduardo Sosa; Xiaoling Song; John S Witte; Peter R Carroll; June M Chan Journal: Prostate Date: 2014-10-04 Impact factor: 4.104
Authors: Scott R Bauer; Erin L Richman; Eduardo Sosa; Vivian Weinberg; Xiaoling Song; John S Witte; Peter R Carroll; June M Chan Journal: Prostate Date: 2013-08-29 Impact factor: 4.104
Authors: Wanling Xie; Ming Yang; June Chan; Tong Sun; Lorelei A Mucci; Kathryn L Penney; Gwo-Shu Mary Lee; Philip W Kantoff Journal: Prostate Date: 2016-02-05 Impact factor: 4.104
Authors: Tobias Nordström; Erin L Van Blarigan; Vy Ngo; Ritu Roy; Vivian Weinberg; Xiaoling Song; Jeffry Simko; Peter R Carroll; June M Chan; Pamela L Paris Journal: Prostate Date: 2015-11-20 Impact factor: 4.104